| # | Country | Total Patents | |
|---|---|---|---|
| #1 | United States | 5 | |
| #2 | WIPO (World Intellectual Property Organization) | 4 | |
| #3 | EPO (European Patent Office) | 3 | |
| #4 | Canada | 2 | |
| #5 | Germany | 2 | |
| #6 | China | 1 | |
| #7 | Israel | 1 |
| # | Industry | |
|---|---|---|
| #1 | Biotechnology | |
| #2 | Pharmaceuticals | |
| #3 | Environmental technology |
| # | Technology | |
|---|---|---|
| #1 | Microorganisms | |
| #2 | Medical preparations | |
| #3 | Therapeutic chemical compounds | |
| #4 | Climate change adaptation technologies |
| # | Name | Total Patents |
|---|---|---|
| #1 | Kochanek Stefan | 17 |
| #2 | Kueppers Claudia | 5 |
| #3 | Kreppel Florian | 5 |
| #4 | Lucas Tanja | 5 |
| #5 | Schraermeyer Ulrich | 3 |
| #6 | Thumann Gabriele | 3 |
| #7 | Schiedner Gudrun | 3 |
| Publication | Filing date | Title |
|---|---|---|
| EP2662451A1 | Nucleic acid construct and use of the same | |
| WO2005106046A1 | Modified viral vector particles | |
| US2006035378A1 | Modified viral vector particles | |
| DE102004021584A1 | New viral vector particle comprising capsid proteins comprising an attachment site comprising cysteine residue, useful in preparing a composition for treating e.g., tumor | |
| DE19955558A1 | Permanent amniocyte cell line, its production and use for the production of gene transfer vectors |